Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Aïda Amer/Axios. Stock: Getty Images
The world's first human trial of whether a drug can essentially make a person's cells younger sets up a reality check for one of the longevity field's most promising theories.
Why it matters: The early-stage clinical trial will signal whether "cellular reprogramming" can be performed safely in humans, a prerequisite for any future claim that a treatment can slow or even reverse biological aging.
